Literature DB >> 11556833

Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?

J Anderson1, T Gordon, A McManus, T Mapp, S Gould, A Kelsey, H McDowell, R Pinkerton, J Shipley, K Pritchard-Jones.   

Abstract

Rhabdomyosarcoma has 2 major histological subtypes, embryonal and alveolar. Alveolar histology is associated with the fusion genes PAX3-FKHR and PAX7-FKHR. Definition of alveolar has been complicated by changes in terminology and subjectivity. It is currently unclear whether adverse clinical behaviour is better predicted by the presence of these fusion genes or by alveolar histology. We have determined the presence of the PAX3/7-FKHR fusion genes in 91 primary rhabdomyosarcoma tumours using a combination of classical cytogenetics, FISH and RT-PCR, with a view to determining the clinical characteristics of tumours with and without the characteristic translocations. There were 37 patients with t(2;13)/PAX3-FKHR, 8 with t(1;13) PAX7-FKHR and 46 with neither translocation. One or other of the characteristic translocations was found in 31/38 (82%) of alveolar cases. Univariate survival analysis revealed the presence of the translocation t(2;13)/PAX3-FKHR to be an adverse prognostic factor. With the difficulties in morphological diagnosis of alveolar rhabdomyosarcoma on increasingly used small needle biopsy specimens, these data suggest that molecular analysis for PAX3-FKHR will be a clinically useful tool in treatment stratification in the future. This hypothesis requires testing in a prospective study. Variant t(1;13)/PAX7-FKHR appears biologically different, occurring in younger patients with more localised disease. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11556833      PMCID: PMC2375077          DOI: 10.1054/bjoc.2001.2008

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

Review 1.  12q13 abnormality in rhabdomyosarcoma. A nonrandom occurrence?

Authors:  P Roberts; C F Browne; I J Lewis; C C Bailey; R D Spicer; J Williams; G Batcup
Journal:  Cancer Genet Cytogenet       Date:  1992-06

2.  Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.

Authors:  K M Kelly; R B Womer; P H Sorensen; Q B Xiong; F G Barr
Journal:  J Clin Oncol       Date:  1997-05       Impact factor: 44.544

3.  Closely linked loci on the long arm of chromosome 13 flank a specific 2;13 translocation breakpoint in childhood rhabdomyosarcoma.

Authors:  M Valentine; E C Douglass; A T Look
Journal:  Cytogenet Cell Genet       Date:  1989

4.  Cytogenetic abnormalities in 42 rhabdomyosarcoma: a United Kingdom Cancer Cytogenetics Group Study.

Authors:  T Gordon; A McManus; J Anderson; T Min; J Swansbury; K Pritchard-Jones; J Shipley
Journal:  Med Pediatr Oncol       Date:  2001-02

5.  Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.

Authors:  R J Davis; C M D'Cruz; M A Lovell; J A Biegel; F G Barr
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

6.  Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma.

Authors:  N Galili; R J Davis; W J Fredericks; S Mukhopadhyay; F J Rauscher; B S Emanuel; G Rovera; F G Barr
Journal:  Nat Genet       Date:  1993-11       Impact factor: 38.330

7.  Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations.

Authors:  E C Douglass; D N Shapiro; M Valentine; S T Rowe; A J Carroll; R B Raney; A H Ragab; S M Abella; D M Parham
Journal:  Med Pediatr Oncol       Date:  1993

8.  Rhabdomyosarcoma. A new classification scheme related to prognosis.

Authors:  M Tsokos; B L Webber; D M Parham; R A Wesley; A Miser; J S Miser; E Etcubanas; T Kinsella; J Grayson; E Glatstein
Journal:  Arch Pathol Lab Med       Date:  1992-08       Impact factor: 5.534

9.  Molecular differential pathology of rhabdomyosarcoma.

Authors:  H Scrable; D Witte; H Shimada; T Seemayer; W W Sheng; S Soukup; A Koufos; P Houghton; B Lampkin; W Cavenee
Journal:  Genes Chromosomes Cancer       Date:  1989-09       Impact factor: 5.006

10.  Rapid VAC high dose melphalan regimen, a novel chemotherapy approach in childhood soft tissue sarcomas.

Authors:  C R Pinkerton; J Groot-Loonen; A Barrett; S T Meller; D Tait; S Ashley; T J McElwain
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

View more
  23 in total

1.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

2.  Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.

Authors:  Pooja Hingorani; Edoardo Missiaglia; Janet Shipley; James R Anderson; Timothy J Triche; Mauro Delorenzi; Julie Gastier-Foster; Michele Wing; Douglas S Hawkins; Stephen X Skapek
Journal:  Clin Cancer Res       Date:  2015-10-15       Impact factor: 12.531

3.  Pax3-FKHR knock-in mice show developmental aberrations but do not develop tumors.

Authors:  Irina Lagutina; Simon J Conway; Jack Sublett; Gerard C Grosveld
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

Review 4.  PAX3-FOXO1 fusion gene in rhabdomyosarcoma.

Authors:  Corinne M Linardic
Journal:  Cancer Lett       Date:  2008-05-23       Impact factor: 8.679

Review 5.  Gene translocations in musculoskeletal neoplasms.

Authors:  Balaji Krishnan; Gaurav Khanna; Denis Clohisy
Journal:  Clin Orthop Relat Res       Date:  2008-06-20       Impact factor: 4.176

6.  New miRNA labeling method for bead-based quantification.

Authors:  Alberto Biscontin; Silvia Casara; Stefano Cagnin; Lucia Tombolan; Angelo Rosolen; Gerolamo Lanfranchi; Cristiano De Pittà
Journal:  BMC Mol Biol       Date:  2010-06-16       Impact factor: 2.946

Review 7.  Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas.

Authors:  N J Sebire; M Malone
Journal:  J Clin Pathol       Date:  2003-06       Impact factor: 3.411

Review 8.  Molecular genetics of pediatric soft tissue tumors: clinical application.

Authors:  Chung-Che Chang; Vinod B Shidham
Journal:  J Mol Diagn       Date:  2003-08       Impact factor: 5.568

Review 9.  Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature.

Authors:  D A Morgenstern; H Rees; N J Sebire; J Shipley; John Anderson
Journal:  Pathol Oncol Res       Date:  2008-05-21       Impact factor: 3.201

Review 10.  Clinical relevance of molecular genetics to paediatric sarcomas.

Authors:  Olga Slater; Janet Shipley
Journal:  J Clin Pathol       Date:  2007-04-27       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.